Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer

This trial asks whether eating a Mediterranean-style diet, losing weight through calorie restriction, or doing both together changes the biochemical environment in the gut in ways that could lower the risk of colorectal cancer (CRC). The gut microbiome converts bile acids produced by the liver into secondary forms, some of which promote cancer and some of which are protective — the ratio between these forms is thought to be a key lever in CRC risk. African Americans (AAs) bear a disproportionate CRC burden and are underrepresented in dietary intervention trials, making this a population-specific gap the study directly targets. The trial randomly assigns 232 obese AA adults aged 45–75 to one of four arms: Mediterranean diet alone (weight-stable), calorie restriction alone (no diet-pattern change), calorie-restricted Mediterranean diet (for weight loss), or a control group, each followed for six months. By isolating diet pattern from weight loss and then combining them, the design lets researchers disentangle which component — food quality, calorie deficit, or their interaction — drives favorable shifts in the bile acid–microbiome axis. The study is registered as completed (as of its listed end date), but no results have been published in the abstract as provided, meaning findings remain pending or unreported here. If results confirm the hypothesis, the trial would provide mechanistic justification for recommending calorie-restricted Mediterranean diets specifically for CRC chemoprevention in a high-risk, underserved population.

• No quantitative results are reported in the available abstract; the trial is registered as completed but findings have not been disclosed in the source record reviewed here.
• The study hypothesizes that a calorie-restricted Mediterranean diet (WL-Med arm) will produce the greatest favorable shift in the bile acid–gut microbiome axis compared with Mediterranean diet alone, weight loss alone, or control — based on prior primate and human observational data cited in the rationale.
• The four-arm design (Med-A, WL-A, WL-Med, Control) in 232 obese African American adults aged 45–75 over 6 months represents one of the largest dietary RCTs specifically powered to examine the bile acid/microbiome axis as a CRC-prevention endpoint in this demographic.

This is a four-arm, parallel-group randomized controlled trial enrolling 232 obese African American adults (BMI criteria implied; ages 45–75) conducted at the University of Illinois at Chicago. Participants were randomized to: Mediterranean diet alone (weight-stable caloric intake), weight-loss lifestyle intervention with no Mediterranean diet pattern (calorie restriction only), calorie-restricted Mediterranean diet targeting weight loss, or a control condition, each lasting six months. Primary outcomes center on the bile acid–gut microbiome axis and its relevance to CRC prevention, with a multidisciplinary team measuring microbial metabolites, bile acid profiles, and anti-cancer metabolite production. The trial was registered on ClinicalTrials.gov (NCT04753359) and is listed as completed.

Because no results data appear in the available source record, all mechanistic conclusions remain provisional and reflect the trial's stated hypotheses rather than observed outcomes — confidence in findings-specific statements is low. The six-month follow-up, while sufficient to detect microbial compositional shifts, may be too short to observe downstream CRC-relevant biomarkers (e.g., polyp burden, mucosal gene expression) and cannot speak to long-term cancer incidence. Restriction to obese African American adults, while scientifically deliberate and addressing a critical disparity gap, limits generalizability to non-obese individuals, other ethnicities, and younger age groups. A logical next experiment would extend the follow-up to 12–24 months, incorporate colonoscopic endpoints (adenoma recurrence), and apply metagenomic sequencing to resolve which specific microbial taxa and bile acid pathways mediate any observed protective effect.

This trial sits at the intersection of dietary intervention, microbial metabolism, and cancer prevention, extending [§101] which characterizes the gut microbiota–bile acid crosstalk (specifically Prevotellaceae NK3B31 and 7-ketolithocholic acid) as a mechanistic driver of metabolic outcomes — here the same axis is interrogated as a CRC-prevention target rather than a metabolic one. It parallels [§72], which examines microbiota remodeling after bariatric surgery for metabolic benefit, but substitutes a dietary and behavioral intervention for a surgical one, offering a less invasive test of whether equivalent microbial rewiring can be achieved. The study also parallels [§100], which frames the human microbiome at a translational crossroads requiring causal evidence from controlled human trials — this RCT's four-arm design directly answers that call by isolating diet pattern from energy deficit as causal variables. The population focus on African Americans with obesity connects it loosely to [§140], which examines microbial and environmental factors in familial adenomatous polyposis, both treating microbial ecology as a modifiable CRC-risk determinant, albeit in very different risk-strata and study designs.

• Letter to the Editor: Gut microbiota–bile acid crosstalk - Prevotellaceae NK3B31 and 7-ketolithocholic acid drive metabolic benefits of distal bowel resection with preservation of terminal ileum
  Directly shares the bile acid–gut microbiome axis as the central mechanistic focus; comparing these two articles clarifies how the same crosstalk pathway operates across dietary intervention versus observational/metabolomic characterization contexts.
• Microbiota remodeling after bariatric surgery: Procedure-specific dynamics and metabolic implications
  Both studies test whether a major intervention can remodel the gut microbiota to yield metabolic and health benefits, but bariatric surgery versus Mediterranean diet represent opposite ends of the intervention-invasiveness spectrum — a useful contrast for gauging how much microbial change diet alone can achieve.
• Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)
  Both articles treat microbial ecology as a modifiable determinant of colorectal cancer risk, but [id=140] focuses on a hereditary high-risk population (FAP) whereas this trial targets obesity-associated sporadic CRC risk in African Americans — comparing them maps where microbiome-targeted prevention may be most tractable.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Provides the theoretical and methodological scaffolding for why an RCT design is needed to move from microbiome association to causal inference; reading it alongside this trial illustrates how the field is attempting to operationalize that translational agenda.